Laser Capture Microdissection for In Situ Antibody Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing cancer-specific antibodies often fail to accurately target cancer cells in patient populations due to changes in cell surface antigens when cancer cells are cultured, and existing techniques struggle to select antibodies that effectively bind to clinically relevant prostate cancer antigens in situ.
Innovation Solution
The development of a method using laser capture microdissection to select antibodies that bind and internalize into prostate cancer cells, generating a panel of phage antibodies targeting clinically represented prostate cancer antigens by restricting antibody selection to binders of internalizing epitopes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If cancer cells are cultured to study their surface antigens, then antibody screening can be performed, but the cell surface antigens change and no longer represent the original tumor
Solution Approach 1:
The patent extracts and analyzes cell surface antigens directly from formalin-fixed paraffin-embedded (FFPE) tissue sections using laser capture microdissection, rather than relying on cultured cell lines. This extraction approach preserves the original tumor antigen profile while enabling antibody screening through the isolated cellular material.
Solution Approach 2:
The patent performs preliminary tissue processing and antigen preservation through formalin fixation and paraffin embedding before antibody screening. This preliminary action maintains the integrity of cell surface antigens in their original tumor state, preventing the changes that occur during cell culture.
2Reliability
If tissue sections from cancer patients are used for antibody selection, then clinically relevant antigens can be targeted, but the tissues are composed of heterogeneous cell populations making selection difficult
Solution Approach 1:
The patent segments the heterogeneous tissue section into individual cancer cells using laser capture microdissection. This segmentation isolates the cancer cells from surrounding stromal and normal cells, enabling selective antibody screening against cancer-specific surface antigens while simplifying the selection process.
Solution Approach 2:
The patent applies local quality by targeting specific cancer cells within the tissue section that express particular surface antigens, rather than treating the entire heterogeneous tissue uniformly. This allows selective pressure to be applied only where needed to enrich for cancer-specific antibody binders.
3Adaptability or versatility
If conventional antibody screening methods are used, then a broad range of antibodies can be generated, but they fail to specifically target cancer cells in patient populations
Solution Approach 1:
The patent implements feedback by using fluorescently labeled secondary antibodies to detect and visualize primary antibody binding to cancer cell surface antigens in FFPE tissue sections. This feedback mechanism allows real-time assessment of antibody specificity and guides the selection of cancer-targeting antibodies with high reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of antibodies that specifically bind and internalize into prostate cancer cells, providing a targeted therapeutic option and enabling efficient delivery of payloads to cancer cells.
Implementation Method 1
laser capture microdissection to select antibodies that bind and internalize into prostate cancer cells
Implementation Method 2
antibodies that specifically bind and internalize into prostate cancer cells
Data Source
AI summary
This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.